National Institute of Allergy and Infectious Diseases (NIAID)s

National Institute of Allergy and Infectious Diseases (NIAID)

179 Protocols (130 Active Accrual of new subjects, 49 Follow-up of previously enrolled subjects)

 03-I-0263:

VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies

 02-I-0286:

Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome

 02-I-0277:

Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells

 02-I-0202:

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral-Naive HIV-Infected Patients

 02-I-0147:

Genetic Studies of Chronic Active Epstein-Barr Virus Infection

 02-I-0110:

Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients

 02-I-0086:

Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity

 02-I-0055:

Evaluation, Treatment, and Follow-up of Patients with Lyme Disease

 01-I-0238:

Host Response to Infection and Treatment in Leishmania Infection of Humans

 01-I-0202:

Natural History, Genetics, Phenotype, and Treatment of Mycobacterial Infections

 00-I-0159:

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

 99-I-0084:

Studies of Human Pneumocystis Infection

 97-I-0096:

Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection

 96-I-0052:

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients with Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations

 95-I-0066:

Genetic Analysis of Immune Disorders

 95-I-0027:

Virologic and Immunologic Evaluation of Lymph Node, Tonsillar and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid

 94-I-0079:

Eosinophil Activation and Function in Parasitic Infections and Other Conditions with Increased Tissue or Peripheral Blood Eosinophilia in Humans

 94-I-0073:

Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes

 93-I-0119:

Detection and Characterization of Host Defense Defects

 93-I-0106:

Cryptococcosis in Previously Healthy Adults

 93-I-0086:

Evaluation and Long-Term Follow-Up of Patients with Acute or Chronic Inflammatory Disorders

 93-I-0063:

Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells

 92-I-0125:

A Study of Viral Burden in Peripheral Blood versus Lymphoid and Bone Marrow Tissue in People living with HIV

 91-I-0140:

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood cells and/or Body Fluids in People Living With and Without HIV

 89-I-0158:

Studies of Immune Regulation in Patients with Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes

 88-I-0083:

Host Response to Infection and Treatment in the Filarial Diseases of Humans

 85-I-0127:

Natural History of Treated Neurocysticercosis and Long-Term Outcomes

 82-I-0183:

A Natural History Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut

 81-I-0164:

Procedures to Obtain Plasma, Lymphocytes, or Other Specimens for Research Studies

 78-I-0023:

Diagnosis and Management of Inflammatory and Infectious Diseases

 001979-I:

A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome with Partial Clinical Response to Eosinophil-Depleting Biologic Agents

 001573-I:

An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-Label Long-Term Ex

 001501-I:

Phase 1 Dose Escalation Study of The Plasmodium Vivax Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-Blocking Activity in Healthy Malaria-Naive Adults

 001078-I:

Phase 1 Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine

 001048-I:

A Phase 1/2 Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-Seronegative Persons

 000889-I:

VRC 615: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB-0115-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults

 000687-I:

VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

 000488-I:

Natural History of Systemic and Nasal Mucosal Immunity after Influenza Vaccination in a Pediatric Population

 000460-I:

A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

 000410-I:

VRC 325 (000410): A Phase I Open-Label Clinical Trial to Evaluate the Dose, Safety, Tolerability and Immunogenicity of Mosaic Quadrivalent Influenza Vaccine with and without Adjuplex Compared with a Licensed Inactivated Seasonal QIV, In Healthy Adults

 000384-I:

Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations

 000320-I:

Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

 000212-I:

Induced Blood-Stage Plasmodium Vivax Infection with HMPBS02-Pv Challenge Agent in Healthy Malaria-Naive Adults to Produce a Plasmodium Vivax Parasite Cell Bank for Future Studies

 21-I-0005:

Phase 1 Study of the Safety and Immunogenicity of an Epstein-Barr virus (EBV) gp350- Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

 20-I-0123:

A Longitudinal Study of COVID-19 Sequelae and Immunity

 19-I-0126:

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

 19-I-0027:

A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects with Indolent Systemic Mastocytosis

 19-I-0003:

A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients with Ebola Virus Disease

 18-I-0139:

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

 18-I-0092:

A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients with Idiopathic CD4 T cell Lymphocytopenia

 18-I-0039:

Challenge Infection of Healthy Adult Volunteers with RSV A2

 18-I-0030:

VRC 603: A Phase 1 Dose-Escalation Study of the Safety of AAV8-VRC07 (VRC-HIVAAV070-00-GT) Recombinant AAV Vector Expressing VRC07 HIV-1 Neutralizing Antibody in Antiretroviral-Treated, HIV-1 Infected Adults with Controlled Viremia

 18-I-0022:

Use of Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients with Leukocyte Adhesion Deficiency Type 1 (LAD1) who have Inflammatory Pathology

 17-I-0072:

Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)

 17-I-0067:

Sanaria PfSPZ Challenge with Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy after Exposure to Only Pre-erythrocytic Stages of Plasmodium falciparum

 16-I-0065:

Screening for Alpha Globin Deletions

 16-I-0053:

A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)

 16-I-0032:

High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease

 15-I-0148:

A Phase I Study of Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers

 15-I-0131:

Xenodiagnosis after Antibiotic Treatment for Lyme Disease - Phase II Study

 15-I-0008:

A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients with X-linked Chronic Granulomatous Disease (CGD)

 14-I-0091:

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

 14-I-0081:

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects with Hypereosinophilic Syndrome (HES)

 14-I-0063:

An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects with Hypereosinophilic Syndrome

 14-I-0009:

Characterization and Management of Patients with HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral Therapy

 13-I-0172:

Phase I Study of the Safety of a Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection

 13-I-0082:

Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases

 13-I-0062:

A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects

 12-I-0103:

Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine

 11-I-0057:

Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy

 10-I-0148:

Natural History of Severe Allergic Inflammation and Reactions

 10-I-0139:

Searching for Persistence of Infection in Lyme Disease

 09-I-0126:

Pathogenesis and Genetic Basis of Physical Induced Urticarial Syndromes

 09-I-0086:

Screening Protocol for Genetic Diseases of Allergic Inflammation

 09-I-0013:

Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults

 08-I-0184:

Studies in the Pathogenesis of Anaphylaxis

 06-I-0153:

A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients with Chronically Elevated Transaminases on Antiretroviral Therapy

 02-I-0080:

The Gemini Study: Study of the Long-Term Safety and Persistence of Cells Following Cell Transfers or Gene Therapy in Identical Twins Discordant for HIV Infection

 88-I-0172:

A Phase III Study with Long-Term Follow-Up of Zidovudine Versus Zidovudine and Alpha-Interferon Versus Alpha-Interferon in Patients with Early HIV Infection

Previous 100 Protocols